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This article presents methods and 
results of surgical treatment and 
radiation therapy of brain metasta-
ses in breast cancer patients (brain 
metastases from breast cancer BMF-
BC). Based on the literature data, it 
was shown that patients with single 
BMF-BC, aged less than 65 years, with 
Karnofsky score (KPS) of 70 or more 
and with cured or controlled extracra-
nial disease are the best candidates 
to surgical treatment. Irrespective of 
the extracranial disease control sta-
tus, there are indications for surgery 
in patients with symptomatic mass 
effect (tumour diameter larger than 
3 cm) and patients with obstructive 
hydrocephalus from their BMF-BC. 
Stereotactic radiosurgery (SRS) has 
some advantages over surgery, with 
similar effectiveness: it may be used 
in the treatment of lesions inaccessi-
ble to surgery, the number of lesion is 
not a  limiting factor if each lesion is 
small (< 3) and adequate doses can 
be delivered, it is not contraindicat-
ed in patients with active extracrani-
al disease, it does not interfere with 
ongoing systemic treatment, and it 
does not require general anaesthesia 
or hospitalisation. A  disadvantage of 
SRS, as compared to whole brain ra-
diotherapy (WBRT), in patients with 
BMF-BC is the possibility of subse-
quent development of new lesion in 
the non-irradiated field. Thus the ma-
jority of the BMF-BC patients are not 
good candidates to surgery or SRS; 
WBRT alone or combined with a sys-
temic treatment still plays a major role 
in the treatment of these patients.
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Introduction
Breast cancer (BC) is the second, after lung cancer (40–50%), most com-
mon cause of brain metastases (brain metastases from breast cancer – 
BMF-BC) (15–25%), and in this respect it comes before melanoma (5–15%) 
and renal and colorectal cancers [1–6]. At diagnosis of a BC of a locoregional 
extent, the risk of BMF-BC development is about 5% [4, 7–9], but in patients 
with a generalized BC it reaches 7–17% [1, 2, 4, 7, 9–12], and in 1.3% of pa-
tients BMF-BC are the first symptom of a metastatic disease [7, 9]. At autop-
sy, BMF-BC are found in about 30% of patients who died of BC, and in the 
group of patients with metastatic disease in 6 or more locations this per-
centage rises up to 86% [1, 2, 4]. The incidence of BMF-BC is systematically 
increasing due to: increasing incidence of cancers related to population age-
ing, improved survival of BC patients associated with adjuvant treatment 
and better efficacy of systemic treatment of generalised BC, and also due to 
the progress in imaging technology (CT, MRI, PET) [1, 3, 5, 10, 13].
BMF-BC usually develop in late, advanced stages of the neoplastic process 
and in general they are preceded by extracranial distant metastases, e.g. bone, 
liver or lung metastases [2, 4, 5, 14]. Median time between BC diagnosis and 
BMF-BC occurrence is 2–3 years and varies significantly between different BC 
subtypes, as follows: 28, 36, 47 and 54 months for triple negative, HER2+, lu-
minal B and luminal A disease, respectively [1, 15–19]. 
Particular molecular subtypes of breast cancer have different predilection 
for brain metastasis (BM) and thereby different effect on life expectancy. 
TNBC and HER2+ patients have the worst prognosis [20, 21]. The situation 
has changed recently when the transtuzumab therapy has become widely 
available, that improves OS in this group of patients. Both these types of 
cancer show particularly high incidence of intracranial spread, reaching: 25–
46% in the TNBC population and 15–44% in the HER2+ population [21–24].
Numerous risk factors for BMF-BC occurrence are known, such as: age 
less than 50 years, negative hormone receptor status, HER2 over-expression, 
high (G3) tumour grade, regional lymph node metastases, advanced extra-
cranial disease (distant metastases in more than 2 locations), presence of 
BRCA 1 mutation, high level of Ki-67 expression, etc. [1–4, 7, 10, 12, 25–29]. In 
the group of patients with generalised BC, the risk of BMF-BC occurrence is 
clearly related to the histological BC subtype and is 35% for HER2+ tumours, 
20% for triple negative disease and only 3% for luminal A breast cancer 
[30, 31]. 
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In general, anty-HER 2 treatment does not reduce the 
incidence of BMF-BC, however it delays their occurrence 
(13 months vs. 2 months) and improves survival (11.6 vs. 
6.1 months) [13, 32]. 
General treatment results
Development of BMF-BC is associated with unfavour-
able prognosis [1, 3–5, 7, 15, 33–36], and median survival 
ranges from 2 to 16 months, depending on many prog-
nostic factors (age and performance status of the patient, 
molecular cancer subtype, extracranial disease extent, 
number of BMF-BC, BMF-BC-free survival and treatment 
used [1–3, 5, 12, 15, 16, 35, 36]. Recursive partitioning anal-
ysis (RPA) index, developed by Gaspar et al. [37], is also 
a prognostic factor. Aoyama performed analysis of 16 
publications presenting the results of brain metastases 
treatment with various methods; 7 publications pertained 
to metastases from various cancers, among which BMF-
BC constitutes only 10–18%, 2 publications included only 
non small-cell lung cancer (NSCLC) metastases, and next 
7 publications – only BMF-BC [38]. Aoyama’s analysis has 
shown that the median survival time for breast cancer and 
other cancers was similar and was: 17.6 and 14.6 months 
for RPA class I, 10.6 and 10.1 month for RPA class II, and 3.0 
and 4.4 months for RPA class III, respectively. It should be 
stressed that about 20% of patients with BMF-BC survive 
12 months since their occurrence [3–5, 16, 33, 34].
Median survival of untreated patients with BMF-BC is 
slightly more than 1 month, of patients receiving palliative 
corticosteroid treatment – up to 2 months, of patients sub-
ject to WBRT – 3–6 months, and extends to 10–12 months 
in the group of patients with 1–3 BMF-BC treated with 
surgery or stereotactic radiosurgery (SRS) with or without 
subsequent whole brain radiotherapy (WBRT) [1, 16, 39].
Treatment methods
The following methods are used in the treatment of 
BMF-BC: surgery, SRS, WBRT, systemic treatments and var-
ious combinations of these methods [5, 7, 26, 38–50]. In 
general, local (surgery, SRS) [5, 7, 38, 40, 46–49] or regional 
(WBRT) [5, 7, 38, 39, 42, 43, 50] treatment is preferred, or 
combination of surgery and radiotherapy. There is a grow-
ing role of systemic treatments, in particular of targeted 
therapies [5, 7, 26, 43–47].
Local treatment
There are no controlled clinical studies entirely dedicat-
ed to the treatment of BMF-BC; in phase III studies con-
ducted so far, the most prevalent group, 52.4–77% was the 
group of patients with brain metastases from NSCLC, and 
only 6.8–19% of patients had BMF-BC [7, 38]. These stud-
ies have shown that local treatment (surgery, SRS) used as 
an add-on to WBRT improves local control in patients with 
1–3 BMF-BC and survival of patients with single BMF-BC. It 
was also found that WBRT adjuvant to the local treatment 
in patients with 1–3 BMF-BC significantly increases brain 
disease control but has no significant effect on patients’ 
survival.
Surgery
The best candidates for surgery are patients:
• with a single BMF-BC at a surgically accessible location, 
• aged < 65 years,
• with Karnofsky score (KPS) of 70 or more, 
• with cured or controlled extracranial disease.
Table 1. RTOG devised prognostic groups
Classes Median survival 
(months)
Class I K ≥ 70
< 65 years of age with 
primary control no extra
cranial metastases 
7.1
Class II all others 4.2
Class III K < 70 2.3
Table 2. Single brain metastasis ASTRO guideline
Survival time – 3 month 
or more





Good prognosis Poor prognosis
Metastasis size  
≤ 3–4 cm
Metastasis size  
> 3–4 cm
Metastasis size  
≤ 3–4 cm
Metastasis size  
> 3–4 cm
Surgery and WBRT Surgery and WBRT Radiosurgery and 
WBRT
WBRT WBRT
Radiosurgery and WBRT Surgery with radiosurgery/








Irrespective of the extracranial disease control status, 
there are indications for surgery in: 
• the rare breast cancer patients with an isolated BMF-BC 
(the only evidence of the disease),
• patients with symptomatic mass effect (tumour diame-
ter larger than 3 cm), 
• patients with obstructive hydrocephalus from their BMF-
BC or at high risk for obstructive hydrocephalus from 
a large posterior fossa BMF-BC abutting the fourth ven-
tricle [42, 51, 52]. 
Stereotactic radiosurgery
Similarly as for surgical treatment, patients with a sin-
gle BMF-BC, with a KPS of 70 and more, with cured or 
controlled extracranial disease are the best candidates for 
SRS; in this setting, the efficacy of SRS is similar to that of 
surgery [51]. SRS has however some advantages:
• it is not limited by BMF-BC location in the brain and it 
may be used in all cerebral regions, including those not 
accessible to surgery (e.g. the brainstem),
• the number of lesions is not a limiting factor for SRS if 
each lesion is small and adequate doses can be delivered 
(15–24 Gy),
• possible active extracranial disease is not a contraindi-
cation for SRS,
• multiple BMF-BC may be treated in one outpatient ses-
sion,
• it does not interfere with ongoing systemic treatment,
• it does not require general anaesthesia or hospitalisa-
tion,
• there is no risk of craniotomy-related complications.
A limitation of SRS, in contrast to surgery, is its un-
suitability for the treatment of BMF-BC lesions exceeding 
3–3.5 cm in the largest diameter. Additionally, surgery can 
immediately relieve symptomatic mass effect and it usu-
ally guarantees more complete and faster resolution of 
vasogenic edema [4, 38, 48–52].
A disadvantage of SRS, as compared to WBRT, in pa-
tients with BMF-BC, is the subsequent development of 
new lesion in the non-irradiated field [7, 49, 53]. On the 
other hand, WBRT causes the problem of late neurotoxici-
ty [7, 54, 55]; Chang et al. compared the neurocognitive re-
sults of SRS alone versus SRS plus WBRT in a randomized 
controlled trial of 1–3 newly diagnosed brain metastases; 
patients who underwent SRS plus WBRT were at a great-
er risk of a significant decline in learning and memory 
function by 4 months [54]. Abe and Aoyama tried to de-
fine patients with brain metastases with a longer survival 
prognosis, in whom it would be possible to avoid adjuvant 
WBRT following SRS [55, 56].
In the analysis of 17 publications cited above, Aoyama 
[38] has shown that:
• the percentage of patients with RPA III (very poor out-
come) was higher in studies including breast cancer pa-
tients than in those including brain metastases of any 
origin (median percentage 42% vs. 10%), 
• the percentage of patients with RPA III was low in studies 
in which SRS was the predominant treatment method, 
as compared with those in which WBRT was the main 
method; it is clear that SRS was used only for highly se-
lected patients.
Aoyama suggests using SRS alone only in patients with 
single BMF-BC and KPS ≥ 70, provided that the patient re-
mains under regular and frequent follow-up [7, 38].
The risk of distant brain failure after SRS alone seems 
to be much higher in patients with triple negative breast 
carcinoma [57].
Leptomengeal disease (LMD) in breast cancer patients 
with CSN metastases is associated with poor prognosis and 
represents the terminal stage of the disease. LMD diagnosis 
is confirmed by cerebrospinal fluid cytology or MRI images. 
There were attempts to identify the risk factors of disease 
spread (to the CSN). The analyses performed have shown 
that only the presence of active disease within the chest 
(i.e. lung metastases) is associated with disease spread to 
the CSN. Some authors suggest a secondary hematoge-
neous spread from pulmonary reservoir. Receptor status, 
active liver and bone metastases, tumour morphology, tu-
mor size, number of brain metastases and history of WBRT 
showed no correlation with LMD [58]. SRS offers good local 
control and reduces the risk of late toxicity, as compared to 
other treatment methods but it cannot protect the patient 
from meningeal spread [59–61]. Mean overall survival from 
LMD diagnosis is approximately 6 months [58].
Whole brain radiotherapy
When WBRT is used as adjuvant treatment of BMF-BC 
after surgery or SRS, two aspects should be taken into con-
sideration: on one hand, this is late neurotoxicity of WBRT, 
and on the other hand – the risk of development of brain 
metastases outside the region treated locally; the latter 
one is of particular importance in breast cancer patients 
[7, 38, 51, 55, 62, 63].
WBRT alone is indicated first of all in patients not 
amenable to surgery or SRS, with KPS < 70, with numerous 
BMF-BC, and with uncontrolled extracranial disease [7, 50, 
51, 64]. None of the WBRT fractioning regimens has shown 
a clear advantage; however fraction doses exceeding 
3 Gy are decidedly avoided, due to an increased risk of late 
post-irradiation neurological damage [7, 50, 51, 65]. The 
regimen of 30 Gy administered in 10 fractions over a peri-
od of 2 weeks is the most commonly used [7, 50, 51]. In the 
group of patients with BMF-BC some authors use lower 
Table 3. Multiple brain metastasis ASTRO guideline
Survival time – 3 month 
or more
Survival time 
– less than  
3 month
Good prognosis Good prognosis Poor 
prognosis





Radiosurgery and WBRT Surgery and WBRT WBRT
Radiosurgery WBRT Palliative care
WBRT
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fraction doses, administering the total dose of 40 Gy in 20 
fractions (fraction dose – 2 Gy) [50, 51]. The rationale for 
such fractionation is the possibility of reduction of the risk 
of late radiation-induced encephalopathy with neurocog-
nitive disturbances that is main late complication of WBRT 
[50, 51, 66, 67]. It should be stressed that breast cancer 
is a relatively radiosensitive tumour; additionally, patients 
with generalised breast cancer live currently much longer, 
owing to effective systemic treatment which increases the 
risk of emergence of late post-irradiation injuries [50, 51].
Median survival after WBRT ranges from 3 to 6 months, 
and objective response to the treatment of BMF-BC is 
achieved in 30–60% of patients [7, 41, 50, 68].
However in about one half of patients undergoing 
WBRT it is not effective enough and these patients die of 
BMF-BC progression [50, 51, 64]. Nieder et al. suggest that 
frequency and duration of response to WBRT is higher in 
patients with breast cancer, as compared to patients with 
e.g. non small cell lung cancer, renal cancer or melanoma 
[68]. There are ongoing studies on reduction of WBRT tox-
icity by using e.g. irradiation technique with hippocampus 
shielding, intensity modulated radiotherapy, neuroprotec-
tors, and on enhancement of WBRT efficacy by its combi-
nation with systemic treatment [7, 26, 45, 50, 64].
One year or more after WBRT patients treated with this 
method start to present symptoms of late radiation toxici-
ty to the white matter. This includes demyelination and in-
jury to the population of periventricular stem cells respon-
sible for repair processes within the CSN. White matter 
changes (WMC) manifest as neurocognitive decline, mem-
ory and behaviour disturbances, reaction slow-down and 
predilection for substances of abuse [69]. WMC diagnosis 
is based on imaging findings. White matter damage is vis-
ible T2 – weighed or FLAIR MRI scans in more than 70% 
of (irraditated) patients. In patients receiving SRS these 
lesions occur significantly less frequently [70]. Women 
with 1–3 intracranial metastases demonstrated remark-
ably higher neurotoxicity after WBRT plus SRS than wom-
en who were treated with SRS alone [71]. Some recent re-
ports show that the irradiated volume has a higher effect 
on survival than the number of irradiated metastases [72]. 
Along with metastatic breast cancer patient survival pro-
longation, availability of new treatment technologies and 
possibility to combine or repeat treatments, the issue of 
neurotoxicity becomes more and more serious [73].
In conclusion, the majority of the BMF-BC patients are 
not good candidates to surgery or SRS, and WBRT alone 
or combined with a systemic treatment still plays a major 
role in the treatment of these patients.
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